DEPLOYDatabase

Company

Abbott

Abbott Laboratories is an American healthcare company based in Abbott Park, Illinois, developing continuous glucose monitoring systems (FreeStyle Libre, Lingo)…

Track AbbottGet notified of verified changes
Founded
1888
HQ
Abbott Park, IL
Status
public (NYSE: ABT)

Models

1

Deployments

1

Overview

Abbott Laboratories is an American healthcare company based in Abbott Park, Illinois, developing continuous glucose monitoring systems (FreeStyle Libre, Lingo) with biometric sensors and wearable health monitoring technology for diabetes management.

Verified record

Verified deployments
1 deployment on file
Active incidents
None on file

DEPLOY Intelligence

Market intelligence for physical AI

Analyst-grade signals, competitive tracking, and investment context across the global physical AI landscape. Launching 2026.

Key facts

Product

Lingo OTC glucose biosensor (FDA 510(k) K233655, May 2024) + adaptive insight app (Lingo Count); built on FreeStyle Libre.

Boundary

Glucose-biometric + adaptive insight -> narrow INCLUDE; AI is adaptive/algorithmic, NOT generative (not at Stelo parity).

Ticker

NYSE: ABT

Business unit

Abbott Diabetes Care

Target population

Non-diabetic / wellness consumers, adults 18+ not on insulin

Data & sources

Press releases

1

Government records

1

Web sources

1

3 sources backing this record.View all →

Models (1)

View all models →

Current platform

Lingo

Lingo is Abbott's over-the-counter continuous glucose monitor biosensor for non-diabetic and wellness consumers, built on the FreeStyle Libre sensor platform, and it is recorded in the biometric form factor as a narrow boundary include and the second glucose example alongside Dexcom Stelo. Made by Abbott, listed on the New York Stock Exchange as ABT through its Abbott Diabetes Care unit, Lingo is a disposable biosensor worn on the back of the upper arm for up to fourteen days using a glucose-oxidase amperometric assay, and it was cleared by the FDA under 510(k) K233655 on May 29, 2024, as a Class II integrated continuous glucose monitoring system for adults eighteen and older who are not on insulin, explicitly not for the diagnosis of any disease including diabetes, a posture directly parallel to Stelo. Its app provides a real-time glucose graph, a Lingo Count daily glucose-spike metric with adaptive targets, food and activity logging, algorithm-driven personalized recommendations, Lingo Challenges behavioral nudges, and Lingo Live sessions with human Abbott nutritionists, with entry pricing of about fifty-four dollars for a two-week single-biosensor starter plan and recurring biweekly and monthly multi-sensor tiers. Glucose is in the biometric definition and Lingo is biometric-primary, and it clears the medical-sensor-without-meaningful-AI exclusion bar on insight-layer substance, since the Lingo Count, adaptive targets, and personalized food-response recommendations are the differentiator versus a bare continuous-glucose graph that Abbott deliberately does not sell to this wellness audience, so the device would exist without the insight layer only in a meaningfully degraded form. A critical cap-flag applies: Lingo is not at parity with Stelo on artificial intelligence. Stelo cleared the bar with a genuine generative-AI layer on Google Cloud Vertex AI and Gemini, whereas Lingo's primary sources describe adaptive and rule-based personalization only, with no documented generative-AI layer and no named AI coaching agent, its coaching being algorithmic plus human nutritionists through Lingo Live, so the registry does not grant Lingo Stelo-equivalent AI standing and records it as the borderline case of the cohort that passes on insight-layer substance rather than on generative-AI grounds. The FDA clearance is the strong anchor, and items not verified include any AI comparable to Stelo's generative AI, a named Lingo coaching agent, the older fifty-three-or-eighty-nine-dollar tier figures since the verified entry is about fifty-four dollars for two weeks and is time-sensitive, and any announced generative-AI roadmap for Lingo.

biometricView model →

Abbott on the deployment map

Where Abbott's robots are verified operating. Explore the deployment map by place and type.

Relationships

AAbbottCustomer

Explainers

Plain-language answers to the questions people ask about Abbott, from DEPLOY’s explainer library. Each is written in the language of the question and cross-checked against this registry.

  • What is Abbott Lingo?

    Abbott Lingo is an FDA-cleared adaptive-algorithmic glucose biometric for non-diabetic consumers, FDA 510(k) K233655 May 2024 cleared on the FreeStyle Libre 14-day glucose monitoring platform. Per Agent A Wave 3 biometric ingest: cleared for adults 18+ NOT on insulin (CAP-FLAG IMPORTANCE: distinct from Dexcom G7 which is for diabetics on insulin). ~$54/2wk price point. AI substance is 'Lingo Count' adaptive-algorithmic recommendations + rule-based integration (NOT generative); 'Lingo Live' is human nutritionists NOT AI coach (CAP-FLAG: common aggregator confusion). Editorial throughline: adaptive-algorithmic glucose biometric paired with Stelo's generative AI substance, documenting the within-cell AI-substance gradient across the glucose pair (Stelo = Vertex AI + Gemini Weekly Insights generative; Lingo = Lingo Count adaptive-algorithmic + rule-based). Cohort positioning: glucose biometric archetype within biometric cluster's glucose-cell at adaptive-algorithmic AI substance tier.

Safety record

No incidents on record for Abbott.

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Full safety record: incidents, sourcing, and exposure data →

Operated deployments (1)

Operator customers (1)

Peer companies